Avego

Exciting Leadership News at Ellie Diagnostics! We are thrilled to announce the appointment of Bruk Herbst as the new Chief Executive Officer of Ellie Diagnostics! ?? Bruk brings a wealth of experience in the veterinary and diagnostics industry, along with a passion for innovation and service excellence. Under his leadership, Ellie will continue to advance veterinary diagnostics, providing trusted solutions that empower veterinarians to deliver the best possible care for their patients. At Ellie, we remain committed to our mission of delivering high-quality, accurate and efficient testing services for veterinary professionals. With Bruk at the helm, we look forward to expanding our impact, strengthening partnerships, and driving new growth opportunities in the industry. Please join us in welcoming Bruk to the Ellie Diagnostics family! ?? Read the full press release here ?? https://hubs.la/Q038vKh-0 #PetHealthcareInnovation #EllieCares #VetMed #VeterinaryMedicine #Veterinarians #Diagnostics

https://lnkd.in/eYBDG3vA Sebela Pharmaceuticals Inc.

https://lnkd.in/gKJV2Uzi #VelanCapital

Another key milestone for Saol Therapeutics towards a treatment for PDCD. The FDA granted Priority Review for the SL1009 NDA and has set a goal date of?May 27, 2025, under the Prescription Drug User Fee Act (PDUFA). Full press release can be found on Saolrx.com. https://lnkd.in/egjm42hw

https://lnkd.in/eWF8C3gJ

A major milestone for Saol Therapeutics! https://lnkd.in/ec-QidMh

We are thrilled to share that AtomVie Global Radiopharma (AtomVie) has been featured in the fall issue of BIOTECanada's Insights Magazine! This article highlights our exciting growth and our unwavering commitment to transforming patients' lives with high-quality radiopharmaceuticals. As a leading CDMO in the radiopharmaceutical industry, we are proud to continue expanding our capabilities, with our upcoming 72,300 sq. ft. state-of-the-art facility at the heart of our growth! This new facility, combined with our unmatched expertise in the field, will significantly enhance our ability to support partners' clinical and commercial manufacturing needs, bringing cutting-edge solutions to patients worldwide. ? At AtomVie, we understand the power of collaboration, and we are honored to be part of the Canadian biotech ecosystem that BIOTECanada represents—bringing together innovative biotech companies, global pharma, investors, academia, and more. We are grateful for the continued support of our partners as we drive growth in healthcare and expand the possibilities of radiopharmaceuticals. ? Be sure to read and share the magazine, https://lnkd.in/g_6T_5eE and explore AtomVie's featured article in the image below! ? #AtomVieGlobalRadiopharma #Canada #Collaboration #CommercialManufacturing #Radiopharmaceuticals?

Good news! The FDA granted Fast Track designation to ALE.P02, our first-in-class antibody-drug conjugate (ADC) targeting Claudin-1. The designation is granted for the treatment of advanced or metastatic CLDN1+ squamous cell tumors, irrespective of the organ of origin. Watch the video with Stella Augustus, our Head of Regulatory Affairs, on why this designation is remarkable. A Phase 1/2 clinical trial of ALE.P02 is planned to start Q1 2025 in patients with CLDN1+ lung, head and neck, cervical or esophageal squamous cancers. Read the full press release: https://lnkd.in/edVdnbkQ #AlentisTherapeutics #FastTrack #FDA #ADC #CLDN1 #Claudin #Oncology

We are delighted to announce the successful closing of an oversubscribed Series D financing, raising $181.4M to develop a deep pipeline of CLDN1 targeted medicines for solid tumors. The funding was supported by a syndicate of top-tier biotech investors including OrbiMed as lead and Novo Holdings and JEITO as co-leads as well as substantial contributions from Frazier Life Sciences, Longitude Capital, RA Capital Management, and Catalio Capital Management. This financing is a testament to the transformational potential of CLDN1 targeted medicine in oncology, in particular our first-in-class antibody-drug conjugates (#ADCs) ALE.P02 and ALE.P03. We’re excited to start Phase 1/2 clinical trials for both programs in 2025. Read the full press release: https://lnkd.in/eVSGPG5G We extend our deepest gratitude to our investors for their trust and support. Together we are making a difference ???? #AlentisTherapeutics #Biotech #Funding #Healthcare #LifeSciences #ADC #CLDN1 #Claudin

Congrats to the Evommune team to close the series C, and welcome to join the Avego portfolio! #Evommune #Avego